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The pathogenesis of encephalitis associ-
ated with the respiratory pathogen Myco-
plasma pneumoniae is not well understood. A
direct infection of the central nervous
system (CNS) and an immune-mediated
process have been discussed [1]. Recent
observations suggest that intrathecally
detectable antibodies against the bacteri-
um, which can serve to establish the
etiology of encephalitis, may indeed me-
diate the disease.
Mycoplasma pneumoniae is a major cause of
upper and lower respiratory tract infections
in humans worldwide, particularly in
children [2,3]. Up to 40% of community-
acquired pneumonia in children admitted
to the hospital are attributed to M.
pneumoniae infection [4–7]. Although the
infection is rarely fatal, patients of every age
can develop severe and fulminant disease.
Apart from the respiratory tract infection,
M. pneumoniae can cause extrapulmonary
manifestations. They occur in up to 25% of
manifest M. pneumoniae infections and may
affect almost every organ, including the
skin as well as the hematologic, cardiovas-
cular, musculoskeletal, and nervous system
[8]. Encephalitis is one of the most
common and severe complications [1]. M.
pneumoniae infection is established in 5%–
10% of pediatric encephalitis patients
[9,10], and up to 60% of them show
neurologic sequelae [10,11].
It is important to establish the cause of
encephalitis at an early stage in order to
specifically treat what can be treated and
to avoid unnecessary treatment. The
diagnosis of M. pneumoniae encephalitis is
challenging. The current diagnostic algo-
rithm of the ‘‘Consensus Statement of the
International Encephalitis Consortium’’
[12] recommends for the diagnosis of M.
pneumoniae infection in children with en-
cephalitis (1) serology and polymerase
chain reaction (PCR) from throat samples
(routine studies), and if positive test results
and/or respiratory symptoms are present,
then (2) additionally PCR in cerebrospinal
fluid (CSF) (conditional studies).
However, M. pneumoniae serology and
PCR in the respiratory tract cannot
discern between colonization and infection
in a clinically relevant time frame [13].
The main reason for this is the relatively
high prevalence of M. pneumoniae in the
upper respiratory tract of healthy children
(up to 56%) [13,14]. The demonstrated
positive serological results in such asymp-
tomatic PCR-positive children (positive
immunoglobulin (Ig) M in 17%, IgG in
24%, and IgA in 6% of 66 cases) [13] may
simply reflect one or more previous
encounters with M. pneumoniae and are
not necessarily related to the presence of
M. pneumoniae in the respiratory tract. It is
clear that this may give rise to an
overestimation of the M. pneumoniae-related
disease burden. A more reliable diagnosis
of M. pneumoniae infection may be achieved
by using paired patient sera in order to
detect seroconversion and/or a 4-fold
increase in antibody titers in addition to
PCR (Table 1; table references: [13,15–
24]). However, such procedures are time-
consuming and are therefore neither
practicable nor useful in an acutely ill
patient.
The detection rate of M. pneumoniae by
PCR in the CSF of M. pneumoniae enceph-
alitis patients is relatively low (0%–14%)
[9,10,25,26]. Moreover, various cases with
M. pneumoniae encephalitis in which bacte-
rial DNA could not be detected in the CSF
had a more prolonged duration of respi-
ratory symptoms before the onset of
encephalitis (.5–7 days) [10,25,27].
These cases indicate that M. pneumoniae
encephalitis may exemplify a postinfec-
tious phenomenon that manifests after
clearance of the bacteria from the CNS
or respiratory tract by the immune system.
The immune response to M. pneumoniae in
the CNS or other sites may also contribute
to the encephalitis (Figure 1; figure
references: [1]).
Interestingly, a promising diagnostic
marker for M. pneumoniae encephalitis has
recently emerged from a few case studies.
In one study, intrathecal synthesis of
antibodies to M. pneumoniae was reported
in 14 cases of M. pneumoniae encephalitis
(74%) [28]. The intrathecal production of
antibodies is generally considered a highly
specific marker for infection of the CNS
[22]. All cases that underwent PCR testing
(93%) indeed had a positive PCR targeting
M. pneumoniae in the CSF [28] even though
it has been recently demonstrated that
intrathecal antibody responses to M.
pneumoniae but not bacterial DNA can be
present at the onset of clinical encephalitis
[29]. In another study, it was reported that
intrathecal antibodies to M. pneumoniae
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were found to cross-react with galactocer-
ebroside C (GalC) in eight out of 21 (38%)
of M. pneumoniae encephalitis cases [30]. All
eight cases showed a negative PCR
targeting M. pneumoniae in CSF. The
cross-reactivity in these cases is likely
induced by molecular mimicry between
bacterial glycolipids and host myelin
glycolipids, including GalC and ganglio-
sides (Figure 2; figure references: [31–34]).
Cross-reactive, anti-GalC antibodies have
previously been detected in patients with
Guillain-Barre´ syndrome (GBS) who suf-
fered from a preceding M. pneumoniae
infection [32,35–38]. GBS is a typical
postinfectious immune-mediated peripher-
al neuropathy [39]. In GBS, cross-reactive
antibodies cause complement activation
and formation of a membrane attack
complex at the peripheral nerves, resulting
in neuromuscular paralysis. Anti-GalC
antibodies have been associated with de-
myelination in patients with GBS [35,38].
Moreover, these anti-GalC antibodies
cause neuropathy in rabbits that are
immunized with GalC [40]. Such anti-
bodies may also be involved in demye-
lination of central nerve cells in M.
pneumoniae encephalitis, as a significant
correlation was found between the pres-
ence of anti-GalC antibodies in the CSF
and demyelination (p=0.026) [30].
Anti-GalC antibodies have not only
been detected in CSF but also in the
serum of M. pneumoniae encephalitis pa-
tients [30,36,41–43], including rates from
13% (2/15) [30] to 100% (3/3) [41],
respectively. It is possible that during
inflammation the blood-brain barrier
(BBB) can become permeable, which
would thereby enable antibodies to cross
the BBB and cause disease. As a conse-
quence, the cross-reactive antibodies in the
CSF of M. pneumoniae encephalitis patients
do not necessarily have to be produced
intrathecally (Figure 1).
M. pneumoniae infections may also be
followed by the production of antibodies
to gangliosides, both in patients with GBS
and in those with encephalitis. In M.
pneumoniae encephalitis, such antibodies
were directed against GQ1b [44,45] or
GM1 [46] (Figure 2). Interestingly, anti-
GQ1b antibodies are associated with a
distinct and severe encephalitis variant,
referred to as Bickerstaff brain stem
encephalitis [47].
In conclusion, while PCR and serology
may be of limited value in the diagnosis of
M. pneumoniae encephalitis, the detection of
intrathecal antibodies to M. pneumoniae,
including cross-reactive antibodies against
GalC and gangliosides, may be regarded
as a promising new diagnostic tool.
The routine diagnostic workup of M.
pneumoniae encephalitis should therefore
aim for the detection of M. pneumoniae
antibodies in both CSF and serum, in
addition to M. pneumoniae PCR in CSF.
Intrathecal antibodies can be detected by
widely accessible enzyme immunoassays
(EIAs) or immunoblotting (Table 1), while
Figure 1. Proposed schematic pathomechanisms in M. pneumoniae encephalitis. (Left) Respiratory tract infection. M. pneumoniae resides
mostly extracellularly on epithelial surfaces. Its close association allows the production of direct injury by a variety of local cytotoxic effects.
Furthermore, it can induce inflammatory responses, elicited by both adhesion proteins and glycolipid epitopes that result in pneumonia. (Right)
Encephalitis. Extrapulmonary disease of the CNS is characterized by systemic dissemination with resultant direct infection and local tissue injury (A) or
immune-mediated injury (B,C). The latter may occur as a result of cross-reactive antibodies against myelin components, e.g., gangliosides and
galactocerebroside C. These antibodies could theoretically have originated from intrathecal synthesis (B) or from outside the CNS (C). Figure adapted
from [1]; see references in the text.
doi:10.1371/journal.ppat.1003983.g001
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intrathecal antibody synthesis can be
established either by calculation of an
antibody index [22] or through parallel
immunoblotting of simultaneously col-
lected CSF and serum samples [48,49].
Antiganglioside antibodies can be detected
routinely by some specialized laboratories,
but their detection together with cross-
reactive antibodies against GalC primarily
serve scientific purposes and may help to
clarify M. pneumoniae antibodies’ immune
target(s). Furthermore, their hypothesized
role in the pathogenesis might provide a
basis for immunomodulatory treatment in
M. pneumoniae encephalitis.
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